In Vivo |
HBV-IN-25 (oral, 5, 20, 100, 300 mg/kg, single) has good PK property, and also shows excellent efficacy in significantly reducing HBV antigens, DNA, and intrahepatic cccDNA levels[1]. Pharmacokinetic Parameters of HBV-IN-25 inHBVcircle mouse model (oral, 5, 20, 100, 300 mg/kg, single)[1]. Dose Terminal body weight % versus day 1 Spinal cord inflammation Foci per 20 cells Spinal cord demyelination Score 0–5 Spinal cord apoptotic cells Count per section PK parameter 5 mg/kg PO 20 mg/kg PO 100 mg/kg PO 300 mg/kg PO Cmax(ng/kg) 828 8157 32200 59900 Tmax(ng/kg) 0.25 0.5 0.5 2.67 AUC0−∞(ng h/mL) 857 11,818 119,960 453,367 t1/2(h) 3.46 3.45 1.82 dose-normalized Cmax[(ng/mL)/(mg/kg)] 166 408 322 200 Dose-normalized AUC0−24h [(ng h/mL)/(mg/kg)] 171 591 1200 1511 Animal Model: HBVcircle mouse model[1] Dosage: 5, 20, 100, 300 mg/kg Administration: oral, 5, 20, 100, 300 mg/kg, single Result:
|